The Native Antigen Company (“NAC”) has been acquired by LGC for up to £18.0m – with the ongoing COVID pandemic highlighting the value of knowledge and execution in the infectious diseases space. Mercia invested in NAC via both its balance sheet and 3rd party funds. The exit represents a strong return for both sources of capital, validating complete connected capital to optimise value creation. For the balance sheet stake, the £5.2m proceeds represent a £2.5m gain on realisation (c.1.5% of our FY ....
09 Jul 2020
Exits Native Antigen Company for strong return, heading to evergreen
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Exits Native Antigen Company for strong return, heading to evergreen
Mercia Asset Management PLC (MERC:LON) | 35.0 0 0.0% | Mkt Cap: 152.0m
- Published:
09 Jul 2020 -
Author:
Andrew Watson -
Pages:
4
The Native Antigen Company (“NAC”) has been acquired by LGC for up to £18.0m – with the ongoing COVID pandemic highlighting the value of knowledge and execution in the infectious diseases space. Mercia invested in NAC via both its balance sheet and 3rd party funds. The exit represents a strong return for both sources of capital, validating complete connected capital to optimise value creation. For the balance sheet stake, the £5.2m proceeds represent a £2.5m gain on realisation (c.1.5% of our FY ....